Ambrx vs Jazz Pharmaceuticals
Ambrx vs Jazz Pharmaceuticals, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Ambrx is on 35/100 and Jazz Pharmaceuticals on 24/100.
Where each one leads
Ambrx
- our overall score: 35/100 against 24/100
- funding raised: $462M against $265M
Jazz Pharmaceuticals
- agent readiness: 33/100 against 22/100
- domain rating: 76/100 against 36/100
At a glance
| Measure | Ambrx | Jazz Pharmaceuticals |
|---|---|---|
| What it is | Clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. | Global biopharmaceutical company focused on oncology and neuroscience treatments. |
| Category | Biotechnology, Drug Discovery, Oncology, Antibody-Drug Conjugates (ADCs) | Biotechnology, Pharmaceuticals, Life Sciences |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Pharmaceuticals |
| Founded | 2003 | 2003 |
| Headquarters | San Diego, United States | Dublin, Ireland |
| Status | Inactive | Active |
Size, funding and growth
| Measure | Ambrx | Jazz Pharmaceuticals |
|---|---|---|
| Total funding | $462M | $265M |
| Latest round | ATM | Post IPO |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Ambrx | Jazz Pharmaceuticals |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 35/100 | 24/100 |
| Traction | 40/100 | 40/100 |
| Team | 70/100 | 70/100 |
| Community | 12/100 | 8/100 |
| Search visibility | Not published | 6/100 |
| Quality | 30/100 | 15/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (22/100) | F (33/100) |
| Domain ratingLink authority, 0-100 | 36/100 | 76/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Ambrx | Jazz Pharmaceuticals |
|---|---|---|
| Hosting | Not detected | AWS |
| Frameworks | Not detected | Bootstrap |
| Open source | No | Yes |
Ambrx vs Jazz Pharmaceuticals: common questions
Which is better, Ambrx or Jazz Pharmaceuticals?
On our 0-100 score Ambrx rates higher (35/100 against 24/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do Ambrx and Jazz Pharmaceuticals compare on the numbers?
Ambrx leads on our overall score (35/100 against 24/100), funding raised ($462M against $265M). Jazz Pharmaceuticals leads on agent readiness (33/100 against 22/100), domain rating (76/100 against 36/100).
Read the full Ambrx review and pricing or the Jazz Pharmaceuticals review and pricing. You can also browse other Ambrx alternatives we track.